Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany
Financial Performance: InterCure Ltd. reported a revenue of NIS 126 million ($34.58 million) for the first half of 2024, down from NIS 147 million in the second half of 2023, largely impacted by damages from the October 7th terror attack on its facility. The company also experienced a total loss of NIS 6,000 compared to a profit of NIS 3.8 million in the same period last year.
Strategic Expansion: The company is expanding its partnership with Cookies into the German market and plans to launch over 30 new GMP SKUs in the second half of 2024, aiming for double-digit growth. InterCure continues to enhance its medical cannabis pharmacy chain, now totaling 24 locations, while expecting compensation from authorities for damages incurred.
Trade with 70% Backtested Accuracy
Analyst Views on OGI
About OGI
About the author
Organigram Reports Q1 Revenue Growth of 48.7%
- Significant Revenue Growth: Organigram's Q1 revenue reached $63.5 million, reflecting a 48.7% year-over-year increase, surpassing market expectations by $9.64 million, indicating strong performance and growth potential in the market.
- Strong International Performance: International revenue amounted to $5.0 million, up 51% year-over-year, demonstrating the effectiveness of the company's global expansion strategy and enhancing the sustainability of its international business.
- Substantial EBITDA Improvement: Adjusted EBITDA rose to $5.3 million, a remarkable 273% increase year-over-year, showcasing significant improvements in cost control and operational efficiency, thereby enhancing profitability.
- Net Income Turnaround: The company reported a net income of $20.0 million compared to a net loss of $27.5 million in the same quarter last year, marking a significant improvement in financial health, boosting investor confidence and laying a solid foundation for future growth.
Organigram Global to Announce Q1 Earnings on February 10
- Earnings Announcement Schedule: Organigram Global is set to release its Q1 2023 earnings report on February 10 before market open, drawing significant attention from investors regarding its performance.
- Earnings Expectations: Analysts have a consensus EPS estimate of -$0.01, indicating challenges in profitability that could impact investor confidence and stock performance.
- Revenue Forecast: The revenue estimate stands at $53.86 million, and any shortfall in actual revenue could negatively affect the stock price and market perception of the company.
- Industry Context: The timing of Organigram's earnings report coincides with other major companies' earnings releases, which may influence market sentiment towards the cannabis industry amid increasing competition.
Organigram Expands Investment in Phylos to $10 Million for Cannabis Genetics
- Strategic Investment Expansion: Organigram Global Inc. has increased its investment in Phylos Bioscience from $7 million to $10 million, aiming to enhance its leadership in seed-based cannabis cultivation by securing priority access to advanced genetics and a robust seed pipeline, which is expected to strengthen its competitive position in both medical and recreational cannabis markets.
- Loan Agreement Revision: The investment includes a revised loan agreement with an additional $3 million advance, maturing on May 25, 2028, ensuring Organigram's exclusivity for selected autoflower cultivars over the next five years, further solidifying its market position.
- Market Share Growth: Through its partnership with Phylos, Organigram plans to scale seed-based production by 2030, which is anticipated to significantly enhance product consistency and economic benefits, thereby meeting the increasing consumer demand.
- Technology-Driven Advantage: Organigram began utilizing seed-based production technology in 2023, marking a transformation in its operational model, which is expected to yield long-term economic benefits and competitive advantages in the market.
Organigram Invests $3 Million to Expand Seed Genetics Strategy
- Innovation Investment: Organigram accelerates its innovation strategy with a $3 million investment in Phylos Bioscience, ensuring delivery of 30 new next-generation genetics annually through 2030, thereby strengthening its leadership in seed-based cultivation.
- International Exclusivity: The company secures five years of exclusivity for its chosen cannabis genetics in international markets including Canada, Australia, the UK, Germany, and Israel, allowing flexibility to add new territories as it expands globally, enhancing its product differentiation strategy.
- Loan Consolidation: Under the amended loan agreement, Organigram consolidates its existing investment with a new $3 million advance, resulting in a total loan principal of $10 million, maturing on May 25, 2028, which enhances the company's financial flexibility.
- Market Advantage: By gaining priority access to Phylos' autoflower genetics, Organigram not only broadens its product portfolio but also provides a significant economic advantage in meeting the needs of consumers and patients, further solidifying its competitive position in both medical and recreational markets.
SA Quant Evaluates Cannabis Stocks Following Trump's Rescheduling Order
Market Reaction to Executive Order: Cannabis stocks faced a decline after President Trump signed an executive order reclassifying marijuana, which, while not legalizing it federally, may offer tax reductions and benefits for cannabis businesses.
Top Performing Stocks: Organigram Global (OGI) leads the list of cannabis stocks with a Buy rating and a YTD performance of 31.06%, while Cresco Labs (CRLBF) and Trulieve Cannabis (TCNNF) follow with Hold ratings and strong YTD gains.
Quant Ratings Overview: Seeking Alpha’s Quant Ratings evaluate stocks based on valuation, growth, momentum, and profitability, with ratings ranging from 1 to 5; a score of 3.5 or above is considered bullish.
Notable YTD Performances: Despite holding ratings, stocks like Ascend Wellness (AAWH) and Jushi Holdings (JUSHF) have shown impressive YTD gains of 176.92% and 170.10%, respectively.
OrganiGram (OGI) Posts Q4 Loss but Exceeds Revenue Projections
Quarterly Performance: OrganiGram reported a quarterly loss of $0.20 per share, significantly worse than the expected loss of $0.01, marking a 1,900% earnings surprise. Revenue for the quarter was $56.91 million, exceeding estimates by 7.1% and up from $32.77 million a year ago.
Stock Outlook: The company's stock has underperformed compared to the S&P 500 this year, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and management's commentary.
Industry Context: OrganiGram operates in the Medical - Products industry, which is currently ranked in the bottom 30% of Zacks industries, suggesting potential challenges ahead. The performance of the stock may be influenced by the overall industry outlook.
Competitor Insights: Tilray Brands, another company in the same industry, is expected to report a quarterly loss of $0.14 per share, with a slight revenue decline anticipated. This highlights the broader challenges facing cannabis producers in the current market environment.
Organigram Reports Q1 Revenue Growth of 48.7%
- Significant Revenue Growth: Organigram's Q1 revenue reached $63.5 million, reflecting a 48.7% year-over-year increase, surpassing market expectations by $9.64 million, indicating strong performance and growth potential in the market.
- Strong International Performance: International revenue amounted to $5.0 million, up 51% year-over-year, demonstrating the effectiveness of the company's global expansion strategy and enhancing the sustainability of its international business.
- Substantial EBITDA Improvement: Adjusted EBITDA rose to $5.3 million, a remarkable 273% increase year-over-year, showcasing significant improvements in cost control and operational efficiency, thereby enhancing profitability.
- Net Income Turnaround: The company reported a net income of $20.0 million compared to a net loss of $27.5 million in the same quarter last year, marking a significant improvement in financial health, boosting investor confidence and laying a solid foundation for future growth.
Organigram Global to Announce Q1 Earnings on February 10
- Earnings Announcement Schedule: Organigram Global is set to release its Q1 2023 earnings report on February 10 before market open, drawing significant attention from investors regarding its performance.
- Earnings Expectations: Analysts have a consensus EPS estimate of -$0.01, indicating challenges in profitability that could impact investor confidence and stock performance.
- Revenue Forecast: The revenue estimate stands at $53.86 million, and any shortfall in actual revenue could negatively affect the stock price and market perception of the company.
- Industry Context: The timing of Organigram's earnings report coincides with other major companies' earnings releases, which may influence market sentiment towards the cannabis industry amid increasing competition.
Organigram Expands Investment in Phylos to $10 Million for Cannabis Genetics
- Strategic Investment Expansion: Organigram Global Inc. has increased its investment in Phylos Bioscience from $7 million to $10 million, aiming to enhance its leadership in seed-based cannabis cultivation by securing priority access to advanced genetics and a robust seed pipeline, which is expected to strengthen its competitive position in both medical and recreational cannabis markets.
- Loan Agreement Revision: The investment includes a revised loan agreement with an additional $3 million advance, maturing on May 25, 2028, ensuring Organigram's exclusivity for selected autoflower cultivars over the next five years, further solidifying its market position.
- Market Share Growth: Through its partnership with Phylos, Organigram plans to scale seed-based production by 2030, which is anticipated to significantly enhance product consistency and economic benefits, thereby meeting the increasing consumer demand.
- Technology-Driven Advantage: Organigram began utilizing seed-based production technology in 2023, marking a transformation in its operational model, which is expected to yield long-term economic benefits and competitive advantages in the market.
Organigram Invests $3 Million to Expand Seed Genetics Strategy
- Innovation Investment: Organigram accelerates its innovation strategy with a $3 million investment in Phylos Bioscience, ensuring delivery of 30 new next-generation genetics annually through 2030, thereby strengthening its leadership in seed-based cultivation.
- International Exclusivity: The company secures five years of exclusivity for its chosen cannabis genetics in international markets including Canada, Australia, the UK, Germany, and Israel, allowing flexibility to add new territories as it expands globally, enhancing its product differentiation strategy.
- Loan Consolidation: Under the amended loan agreement, Organigram consolidates its existing investment with a new $3 million advance, resulting in a total loan principal of $10 million, maturing on May 25, 2028, which enhances the company's financial flexibility.
- Market Advantage: By gaining priority access to Phylos' autoflower genetics, Organigram not only broadens its product portfolio but also provides a significant economic advantage in meeting the needs of consumers and patients, further solidifying its competitive position in both medical and recreational markets.
SA Quant Evaluates Cannabis Stocks Following Trump's Rescheduling Order
Market Reaction to Executive Order: Cannabis stocks faced a decline after President Trump signed an executive order reclassifying marijuana, which, while not legalizing it federally, may offer tax reductions and benefits for cannabis businesses.
Top Performing Stocks: Organigram Global (OGI) leads the list of cannabis stocks with a Buy rating and a YTD performance of 31.06%, while Cresco Labs (CRLBF) and Trulieve Cannabis (TCNNF) follow with Hold ratings and strong YTD gains.
Quant Ratings Overview: Seeking Alpha’s Quant Ratings evaluate stocks based on valuation, growth, momentum, and profitability, with ratings ranging from 1 to 5; a score of 3.5 or above is considered bullish.
Notable YTD Performances: Despite holding ratings, stocks like Ascend Wellness (AAWH) and Jushi Holdings (JUSHF) have shown impressive YTD gains of 176.92% and 170.10%, respectively.
OrganiGram (OGI) Posts Q4 Loss but Exceeds Revenue Projections
Quarterly Performance: OrganiGram reported a quarterly loss of $0.20 per share, significantly worse than the expected loss of $0.01, marking a 1,900% earnings surprise. Revenue for the quarter was $56.91 million, exceeding estimates by 7.1% and up from $32.77 million a year ago.
Stock Outlook: The company's stock has underperformed compared to the S&P 500 this year, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and management's commentary.
Industry Context: OrganiGram operates in the Medical - Products industry, which is currently ranked in the bottom 30% of Zacks industries, suggesting potential challenges ahead. The performance of the stock may be influenced by the overall industry outlook.
Competitor Insights: Tilray Brands, another company in the same industry, is expected to report a quarterly loss of $0.14 per share, with a slight revenue decline anticipated. This highlights the broader challenges facing cannabis producers in the current market environment.
